Andrew Talal, MD, MPH
Andrew Talal, MD, MPH is a physician-scientist with more than 20 years experience in treating hepatitis C virus (HCV), especially among substance users. He is currently a Professor of Medicine at SUNY, University at Buffalo where he has been the principal investigator on a 7-year, $8 million award from the Patient-Centered Outcomes Research Institute to study a facilitated telemedicine model-based HCV treatment among patients in treatment for opioid use disorder. The study consists of 12 telemedicine sites across New York State conducting integrated treatment of HCV and opiate use disorder. The study has also been supported by ~$4 million from the Kaleida Health Foundation over the past 8 years. Dr. Talal was also appointed by the New York Governor to a task force to develop a statewide HCV elimination plan and he also serves on the NYS HCV Guidelines committee. He also has active funding from the NIH to study factors leading to HCV elimination, and he is a practicing hepatologist.
Talal has been honored with a 2025 Top Ten Clinical Research Achievement Award from the Clinical Research Forum and one of three Distinguished Clinical Research Achievement Awards. The awards honor groundbreaking achievements in clinical research from across the nation. The Clinical Research Forum includes the leading academic health centers and medical schools in the country.” “The high impact study from Dr. Talal was recognized nationally because it has had a direct impact in improving health outcomes,” says Timothy Murphy, SUNY Distinguished Professor. “My congratulations to Dr. Talal and his research team for their rigorous methods in demonstrating improved health outcomes that can be implemented widely to the benefit of patients nationally.
The complete article can be found here.
